Baker BROS. Advisors LP grew its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 15.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,885,357 shares of the company's stock after buying an additional 1,485,397 shares during the quarter. Bicycle Therapeutics accounts for 1.6% of Baker BROS. Advisors LP's investment portfolio, making the stock its 12th largest holding. Baker BROS. Advisors LP owned 15.76% of Bicycle Therapeutics worth $152,395,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in BCYC. Barclays PLC boosted its holdings in Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after buying an additional 2,345 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Bicycle Therapeutics in the 4th quarter worth approximately $57,000. JPMorgan Chase & Co. increased its stake in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after purchasing an additional 1,782 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Bicycle Therapeutics by 30.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after purchasing an additional 2,191 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in Bicycle Therapeutics by 35.7% during the third quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock worth $457,000 after purchasing an additional 5,310 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on BCYC. Barclays dropped their price target on Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. B. Riley lowered their price target on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Stephens restated an "equal weight" rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Morgan Stanley set a $17.00 target price on Bicycle Therapeutics and gave the company an "equal weight" rating in a research note on Monday. Finally, JMP Securities dropped their price target on Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating for the company in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $25.00.
View Our Latest Stock Report on Bicycle Therapeutics
Bicycle Therapeutics Price Performance
BCYC stock traded up $0.37 during trading on Wednesday, reaching $7.77. 659,852 shares of the stock traded hands, compared to its average volume of 397,868. The business's 50 day moving average price is $8.53 and its 200-day moving average price is $14.09. The firm has a market capitalization of $537.70 million, a PE ratio of -2.36 and a beta of 1.60. Bicycle Therapeutics plc has a 52-week low of $6.10 and a 52-week high of $28.67.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $9.98 million for the quarter, compared to analyst estimates of $8.67 million. On average, equities research analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.
Bicycle Therapeutics Company Profile
(
Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Recommended Stories
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
